Antitrust matters are rarely isolated within a single state or federal agency or jurisdiction. We represent clients facing multi-dimensional antitrust challenges on the transactional, regulatory and litigation fronts, mobilizing an unmatched combination of courtroom excellence, government experience and legal, economic and academic prowess on our clients’ behalf.

Cigna Secures DOJ Clearance of $67 Billion Express Scripts Acquisition

Cigna announced that the Antitrust Division of the DOJ cleared Cigna’s $67 billion acquisition of pharmacy benefits manager Express Scripts Holding.

» more

New York Judge Dismisses SSA Price-Fixing Class Action Against Nomura

In a victory for client Nomura and other defendant banks, Paul, Weiss and other joint defense firms won the dismissal of a consolidated class action alleging that Nomura and other major global financial institutions conspired to manipulate prices in the multitrillion-dollar global market for supranational, sub-sovereign and agency (SSA) bonds. 

» more

Antitrust Month in Review – February 2019

In February, the much-anticipated decision in the AT&T-Time Warner merger appeal was handed down.  The appeals court found that the district court did not err in denying the Department of Justice’s (DOJ) request to enjoin the deal.

» more

Antitrust Partners Author Article on Senate Antitrust Oversight Hearing

Craig Benson, Joseph Bial, Andrew Forman, Ken Gallo, Jonathan Kanter, William Michael, Rick Rule and Aidan Synnott co-authored an article, "Takeaways From Senate Antitrust Enforcement Hearing," that appeared in the Expert Analysis section of Law360. 

» more

Landmark Antitrust Victory for Becton Dickinson in the Fifth Circuit

Paul, Weiss secured a significant antitrust appellate victory for global medical technology company Becton Dickinson & Company (BD).

» more

Elanco to Acquire Boehringer Ingelheim Vetmedica’s Vaccines Portfolio

As reported in The Wall Street JournalBloombergReuters and other media outlets, Paul, Weiss client Elanco U.S., Inc., a subsidiary of Paul, Weiss client Eli Lilly and Company, announced an agreement to acquire Boehringer Ingelheim Vetmedica, Inc.'s U.S. feline, canine and rabies vaccines portfolio, as well as a fully integrated manufacturing and R&D site, for $885 million. 

» more

D.C. District Court Rejects Request for Preliminary Injunction in Mastercard ATM Fee Rule Case

A federal district court in Washington, D.C. rejected an application to preliminarily enjoin Paul, Weiss client Mastercard Incorporated from enforcing its ATM rules.

» more

Benchmark Litigation Names Paul, Weiss “Antitrust Firm of the Year”

Paul, Weiss has been named Benchmark Litigation's "Antitrust Firm of the Year" for 2015. Litigation partners Aidan Synnott, Jacqueline Rubin and William Michael received the award for the firm on January 29 at the Essex House in New York at the second annual nationwide U.S. Benchmark Litigation Awards ceremony.

» more

© 2019 Paul, Weiss, Rifkind, Wharton & Garrison LLP

Privacy Policy